Aldo‐keto reductases‐mediated cytotoxicity of 2‐deoxyglucose: A novel anticancer mechanism

2‐Deoxyglucose (2DG) is a non‐metabolizable glucose analog currently in clinical trials to determine its efficacy in enhancing the therapeutic effects of radiotherapy and chemotherapy of several types of cancers. It is thought to preferentially kill cancer cells by inhibiting glycolysis because cancer cells are more dependent on glycolysis for their energy needs than normal cells. However, we found that the toxicity of 2DG in cancer cells is mediated by the enzymatic activities of AKR1B1 and/or AKR1B10 (AKR1Bs), which are often overexpressed in cancer cells. Our results show that 2DG kills cancer cells because, in the process of being reduced by AKR1Bs, depletion of their cofactor NADPH leads to the depletion of glutathione (GSH) and cell death. Furthermore, we showed that compounds that are better substrates for AKR1Bs than 2DG are more effective than 2DG in killing cancer cells that overexpressed these 2 enzymes. As cancer cells can be induced to overexpress AKR1Bs, the anticancer mechanism we identified can be applied to treat a large variety of cancers. This should greatly facilitate the development of novel anticancer drugs.

• Publication year

  2018

• Venue

  Cancer Science

• Publication date

  2018-05-03

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1111/cas.13604PMID 29617059PMCID 5989857
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Aldo‐keto reductases‐mediated cytotoxicity of 2‐deoxyglucose: A novel anticancer mechanism

  2018cited by this paper
• The glutathione synthesis inhibitor buthionine sulfoximine synergistically enhanced melphalan activity against preclinical models of multiple myeloma

  2014influential reference
• Combined inhibition of glycolysis, the pentose cycle, and thioredoxin metabolism selectively increases cytotoxicity and oxidative stress in human breast and prostate cancer

  2014cited by this paper
• Influence of GSH synthesis inhibition on temporal distribution of NAD+/NADH during vascular endothelial cells proliferation

  2014cited by this paper
• The emerging role of the Nrf2–Keap1 signaling pathway in cancer

  2013cited by this paper
• Crystal structures of AKR1C3 containing an N-(aryl)amino-benzoate inhibitor and a bifunctional AKR1C3 inhibitor and androgen receptor antagonist. Therapeutic leads for castrate resistant prostate cancer.

  2012cited by this paper
• Glutathione Depletion and Carbon Ion Radiation Potentiate Clustered DNA Lesions, Cell Death and Prevent Chromosomal Changes in Cancer Cells Progeny

  2012cited by this paper
• Expression of the Aldo-Ketoreductases AKR1B1 and AKR1B10 in Human Cancers

  2012cited by this paper
• Simultaneous inhibition of glutathione- and thioredoxin-dependent metabolism is necessary to potentiate 17AAG-induced cancer cell killing via oxidative stress.

  2012cited by this paper
• Glutathione and modulation of cell apoptosis.

  2012cited by this paper
• Susceptibility of Human Head and Neck Cancer Cells to Combined Inhibition of Glutathione and Thioredoxin Metabolism

  2012cited by this paper
• Enzymes of the AKR1B and AKR1C Subfamilies and Uterine Diseases

  2012cited by this paper
• Glutathione in Cancer Cell Death

  2011cited by this paper
• Rifampicin Does not Significantly Affect the Expression of Small Heterodimer Partner in Primary Human Hepatocytes

  2011cited by this paper
• Targeting aldose reductase for the treatment of cancer.

  2011cited by this paper
• Proteasome inhibitors MG-132 and bortezomib induce AKR1C1, AKR1C3, AKR1B1, and AKR1B10 in human colon cancer cell lines SW-480 and HT-29.

  2011cited by this paper
• Human aldo-keto reductases 1B1 and 1B10: a comparative study on their enzyme activity toward electrophilic carbonyl compounds.

  2011cited by this paper
• Polyol pathway impairs the function of SERCA and RyR in ischemic-reperfused rat hearts by increasing oxidative modifications of these proteins.

  2010cited by this paper
• Selective inhibition of the tumor marker AKR1B10 by antiinflammatory N-phenylanthranilic acids and glycyrrhetic acid.

  2010cited by this paper
• Nrf2-dependent upregulation of antioxidative enzymes: a novel pathway for proteasome inhibitor-mediated cardioprotection.

  2009cited by this paper
• Chemosensitizing and cytotoxic effects of 2-deoxy-D-glucose on breast cancer cells.

  2009cited by this paper
• 2-Deoxy-D-glucose enhances TRAIL-induced apoptosis in human melanoma cells through XBP-1-mediated up-regulation of TRAIL-R2

  2009cited by this paper
• Apoptosis and glutathione: beyond an antioxidant

  2009cited by this paper
• Aldo-keto reductase family 1 member B1 inhibitors: old drugs with new perspectives.

  2009cited by this paper
• Type 5 17beta-hydroxysteroid dehydrogenase/prostaglandin F synthase (AKR1C3): role in breast cancer and inhibition by non-steroidal anti-inflammatory drug analogs.

  2009cited by this paper
• Histone Deacetylase Inhibition and Blockade of the Glycolytic Pathway Synergistically Induce Glioblastoma Cell Death

  2008cited by this paper
• Under normoxia, 2-deoxy-d-glucose elicits cell death in select tumor types not by inhibition of glycolysis but by interfering with N-linked glycosylation

  2007cited by this paper
• Human aldo-keto reductases: Function, gene regulation, and single nucleotide polymorphisms.

  2007influential reference
• Cigarette smoke condensate induces cytochromes P450 and aldo-keto reductases in oral cancer cells.

  2006cited by this paper
• Role of aldo-keto reductases in development of prostate and breast cancer.

  2006cited by this paper
• Overexpression of aldose reductase in human cancer tissues.

  2006cited by this paper
• Overexpression of the Aldo-Keto Reductase Family Protein AKR1B10 Is Highly Correlated with Smokers' Non–Small Cell Lung Carcinomas

  2005cited by this paper
• Aldose reductase in diabetic microvascular complications.

  2005cited by this paper
• Detection and identification of tumor‐associated protein variants in human hepatocellular carcinomas

  2004cited by this paper
• Growth-associated changes in glutathione content correlate with liver metastatic activity of B16 melanoma cells

  2004cited by this paper
• Genetic analysis of aldose reductase in diabetic complications.

  2003cited by this paper
• Clinical update: proteasome inhibitors in solid tumors.

  2003cited by this paper
• Heterogeneity in 2-deoxy-D-glucose-induced modifications in energetics and radiation responses of human tumor cell lines.

  2001cited by this paper
• Metabolism of the 2-oxoaldehyde methylglyoxal by aldose reductase and by glyoxalase-I: roles for glutathione in both enzymes and implications for diabetic complications.

  2001cited by this paper
• Glucose Deprivation‐Induced Oxidative Stress in Human Tumor Cells: A Fundamental Defect in Metabolism?

  2000cited by this paper
• The use of fluoro- and deoxy-substrate analogs to examine binding specificity and catalysis in the enzymes of the sorbitol pathway.

  1998cited by this paper
• Identification and Characterization of a Novel Human Aldose Reductase-like Gene*

  1998influential reference
• Substrate specificity of human aldose reductase: identification of 4-hydroxynonenal as an endogenous substrate.

  1995cited by this paper
• Identification of tumor-associated protein variants during rat hepatocarcinogenesis. Aldose reductase.

  1994cited by this paper
• High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis.

  1992cited by this paper
• Cell cycle progression of glutathione-depleted human peripheral blood mononuclear cells is inhibited at S phase.

  1989cited by this paper
• [Origin of cancer cells].

  1956cited by this paper
• Über die Entstehung der Krebszellen

  1956cited by this paper

• Pomegranate peel and ellagic acid attenuate ulcerative colitis by targeting AKR1B1/B3 to inhibit NLRP3.

  2025cites this paper
• Advances and prospects in deuterium metabolic imaging (DMI): a systematic review of in vivo studies

  2024cites this paper
• Exploration and validation of a novel reactive oxygen species–related signature for predicting the prognosis and chemotherapy response of patients with bladder cancer

  2024cites this paper
• Deconvolution of cell-type-associated markers predictive of response to neoadjuvant radiotherapy

  2024cites this paper
• Tempol, a Superoxide Dismutase Mimetic, Inhibits Wallerian Degeneration Following Spinal Cord Injury by Preventing Glutathione Depletion and Aldose Reductase Activation

  2024cites this paper
• LINC00978 regulates metabolic rewiring to promote the malignancy of glioblastoma through AKR1B1.

  2023cites this paper
• Unveiling the veil of lactate in tumor-associated macrophages: a successful strategy for immunometabolic therapy

  2023cites this paper
• In Silico Evaluation of Binding of 2-Deoxy-D-Glucose with Mpro of nCoV to Combat COVID-19

  2022cites this paper
• Glucose Analogue (2-DG): A Novel Therapy for Covid 19

  2021cites this paper
• Managing GSH elevation and hypoxia to overcome resistance of cancer therapies using functionalized nanocarriers

  2021cites this paper
• Neuroprotection Effect of Astragaloside IV from 2-DG-Induced Endoplasmic Reticulum Stress

  2020cites this paper
• The AKR1B1 inhibitor epalrestat suppresses the progression of cervical cancer

  2020cites this paper
• Role of aldo‐keto reductase family 1 member B1 (AKR1B1) in the cancer process and its therapeutic potential

  2020cites this paper
• Reactive oxygen species in cancer: a paradox between pro- and anti-tumour activities

  2020cites this paper
• Pharmacological interventions part IV: Metabolic modifiers

  2020cites this paper
• Thymol mediates bactericidal activity against Staphylococcus aureus by targeting an aldo-keto reductase and consequent depletion of NADPH.

  2019cites this paper
• Self‐Assemble Polymeric Nanoparticle with GSH Exhaustion for SPECT Imaging–Guided Enhanced Radioisotope Therapy

  2019cites this paper
• Pharmacokinetic, Physicochemical and Medicinal Properties of N-glycoside Anti-cancer Agent More Potent than 2-Deoxy-D-Glucose in Lung Cancer Cells

  2019cites this paper
• Aldo‐keto reductases‐mediated cytotoxicity of 2‐deoxyglucose: A novel anticancer mechanism

  2018cites this paper